1. Time to Recurrence (Hormone Receptor-positive Patients)30 HR
0.76
95% CI
(0.67, 0.87)
P-value
0.0001 25
HR+
21.8% 20
Tamoxifen (T) Anastrozole (A)
Patients (%) 15
12.5%
17.0% 10
9.7% 5
Absolute difference
2.8%
4.8% 1 2 3 4 5 6 7 8 9
Follow-up time (years)
At risk: A T
HR=hazard ratio; HR+=hormone receptor-positive; CI=confidence interval
Adapted from Forbes J. SABCS 2007. 1

2. Disease-free Survival (Hormone Receptor-positive Patients)30
29.9% HR
0.85
95% CI
(0.76, 0.94)
P-value
0.003
HR+ 25
25.8% 20
Tamoxifen (T) Anastrozole (A)
16.4% 15
Patients (%) 10
13.9% 5
Absolute difference
2.5%
4.1% 1 2 3 4 5 6 7 8 9
Follow-up time (years)
At risk: A T
HR=hazard ratio; HR+=hormone receptor-positive; CI=confidence interval
Adapted from Forbes J. SABCS 2007.

3. Time to Recurrence: Smoothed Hazard Estimates (Hormone Receptor-positive Patients)
4.0
3.0
Annual hazard rates (%)
2.0
1.0
Tamoxifen (T) Anastrozole (A)
0.0 1 2 3 4 5 6 7 8 9
Follow-up time (years)
Adapted from Forbes J. SABCS 2007.

4. Fracture Episode Rates Throughout the Study4
Tamoxifen (T) Anastrozole (A) 3 2
Annual fracture episode rates (%) 1 1 2 3 4 5 6 7 8 9
Time since randomization (years)
At risk: A T
2984
2976
2859
2824
2745
2699
2640
2572
2496
2419
2306
2208
2077
2000
1713
1645
702
659
Adapted from Forbes J. SABCS 2007.

5. Benefits Continue and Detrimental Effects Decline After Treatment Cessation
Time to recurrence
Fracture episode rates 30 4
Tamoxifen (T)
Anastrozole (A)
Tamoxifen (T)
Anastrozole (A) 25
21.8% 3 20
Patients (%) 15
12.5%
Annual fracture episode rates (%) 2
17.0% 10 1
9.7% 5
Absolute difference
2.8%
4.8% 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
Follow-up time (years)
Time since randomization (years)
Adapted from Forbes J. SABCS 2007.